Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended July 31, 1999.
Business Overview: The Company develops, manufactures, and markets healthcare products through two primary segments: CooperVision (CVI), specializing in contact lenses including toric lenses for astigmatism, and CooperSurgical (CSI), providing diagnostic products and surgical instruments for women's healthcare.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended July 31, 1999 |
9 Months Ended July 31, 1999 |
9 Months Ended July 31, 1998 |
|---|---|---|---|
| Net Sales | $43,404 | $120,106 | $106,543 |
| Gross Profit | $28,288 | $76,400 | $67,366 |
| Gross Margin % | 65% | 64% | 63% |
| Operating Income | $10,895 | $26,421 | $23,093 |
| Net Income | $6,546 | $17,580 | $24,650 |
| Diluted EPS (Continuing Ops) | $0.46 | $1.01 | $1.37 |
| Cash from Operations | N/A | $15,289 | $2,510 |
| Cash & Equivalents | $11,726 | $11,726 | $18,249 (Oct 31, 1998) |
| Total Debt | $62,005 | $62,005 | $90,200 (Oct 31, 1998) |
Note: Total Debt is the sum of current portion of long-term debt ($3,009) and long-term debt ($56,496) as of July 31, 1999.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 9% ($3.7 million) in the third quarter and 13% ($13.6 million) for the nine-month period compared to 1998. CVI core business revenue grew 15% year-over-year.
- Profitability: Operating income rose 16% in the quarter and 14% year-to-date. Gross margins improved to 65% (quarter) and 64% (nine months) from 63% in the prior year, driven by manufacturing efficiencies at CVI and CSI.
- Discontinued Operations: The prior year included significant income from the Hospital Group of America (HGA) psychiatric services business, which was sold in 1999. The 1999 nine-month period includes a $3.1 million gain on the disposal of HGA, whereas 1998 included $3.6 million in net income from discontinued operations.
- Debt Reduction: Total debt decreased from $90.2 million at October 31, 1998, to $62.0 million at July 31, 1999. Proceeds from the HGA sale were used to pay down debt, reducing the debt-to-equity ratio from 0.6:1 to 0.4:1.
- Cash Flow: Operating cash flow for the nine months ended July 31, 1999, was $15.3 million, a significant increase from $2.5 million in the same period in 1998.
Guidance, Outlook, and Risks
- Outlook: Management expects sales to continue growing. Investment in manufacturing capacity is expected to decrease as supply and demand are balanced. Sales and marketing spending at CVI is expected to decrease as new product launches mature.
- Tax Strategy: The Company implemented a global tax plan to minimize reported taxes and actual payments. The effective tax rate (ETR) is projected to be approximately 33% for the full year, with a potential reduction to 30% over the next several years.
- Dividends: The Company initiated an annual cash dividend of 8 cents per share, payable in quarterly installments of 2 cents.
- Year 2000 (Y2K) Compliance: The Company anticipates completing its Y2K compliance program by September 30, 1999. Estimated total costs are approximately $500,000, with $380,000 already expended. Management does not anticipate material Y2K problems but notes risks related to third-party vendors.
- Environmental Contingency: An environmental investigation is underway at a CVI site regarding groundwater contamination. The Company has accrued approximately $500,000 and believes remediation costs will not be material.
Investor Verification Checklist
- Discontinued Operations Impact: Verify the comparability of 1999 earnings to 1998, as 1998 included income from the HGA psychiatric business which was divested in 1999.
- Tax Rate Consistency: Confirm the impact of the change in tax reporting (from utilizing Net Operating Losses in 1998 to a standard provision in 1999) on year-over-year EPS comparisons.
- Debt Structure: Review the specific terms of the remaining $62 million in debt, particularly the variable rate exposure hedged against the London Interbank Offered Rate.
- Y2K Contingency: Assess the status of third-party vendor compliance, as the Company's operations depend on external suppliers who may face Y2K disruptions.
- CVI Market Share: Validate the claim of gaining one market share point in the U.S. contact lens market to 8% and the leadership position (27% share) in the toric lens segment.